R&D Returns Fall to Lowest Level in 9 Years
Projected returns on investment in research and development (R&D) for the top 12 biopharmaceutical companies have fallen to 1.9%, according to a study by Deloitte’s Centre for Health Solutions leveraging revenue forecasts and industry benchmarks generated by GlobalData, a leading data and analytics company.
The study, Unlocking R&D Productivity: Measuring the Return From Pharmaceutical Innovation 2018, published by Deloitte, reveals that returns are down 1.8 percentage points from 3.7% in 2017, and forecast average peak sales are at $408 million, making 2018 the lowest level since Deloitte’s first R&D report in 2010. In the rapidly changing biopharma landscape, R&D returns have dropped by 8.2% percentage points from 10.1% in 2010.
The increase in average cost of development of biopharmaceutical drugs is a driver of this declining return. Average costs of development before regulatory approval for commercialization have increased in 6 out of the past 8 years, with the average cost now at $2,180 million, almost double the cost back in 2010 of $1,188 million.
The study also confirms that a systemic approach to productivity improvement, driven by innovative streamlining approaches, is needed to lessen development costs and timeline, ultimately increasing R&D returns. Companies need to act now and embrace new ways of working, embed new technologies, such as Artificial Intelligence (AI) and Robotic Process Automation (RPA), and seek out talent with the right skill sets to optimize their return on investment in pharmaceutical innovation.
Bonnie Bain, PhD, Global Head of Pharma at GlobalData, said “The good news is that advances in these technologies are already starting to have an impact in R&D. Companies will increasingly use AI, in particular machine learning algorithms, to reduce R&D cycle time, costs, and ultimately build a strong and sustainable drug pipeline. We will also continue to see use of AI extend beyond drug discovery and lead optimization to playing an important role in clinical trials – not only for analyzing the large amounts of data being generated from clinical studies but also for trial recruitment and management.”
In addition to the 12 original cohort companies, since 2015, four smaller and more specialized biopharma companies have been included as an extension cohort of the R&D study.
Consistent with the original cohort, these companies also saw returns decline to 9.3% in 2018, from 12.5% in 2017. However, this drop was mainly driven by the increased costs of commercialization of five high value drugs from the four companies. In line with observations from previous years, these smaller firms continue to outperform their peers, finding success in identifying high value products with significant unmet medical needs. These products have added $70 billion of projected lifetime sales to the commercial portfolio across the four companies. The extension cohort has also increased the forecast peak sales per asset from $952 million in 2013 to $1,165 million in 2018.
Cynthia Brisac, PhD, Senior Strategy Consultant at GlobalData, added “In the past decades, we’ve witnessed a consistent and rapid decline in R&D return in part driven by a shift toward the development of more elaborated biological solutions, for increasingly complex diseases, including ones previously considered as intractable, and in progressively more complicated landscapes. Over time, increased built expertise in carefully prioritized therapeutic areas, complemented with machine learning, may be key to offset some of the risks and costs of bringing new therapies to market.”
*In some cases, minor adjustments have been made to the core data sets for previous years, while this adjusts the overall figure for these years, the trends and conclusions drawn remain consistent. Figures have been adjusted to include deals or trial dates not consistently visible in the pipeline when forecasts were run in the year of the report.
For more information
To gain access to our latest press releases: GlobalData Media Centre. Analysts available for comment. Please contact the GlobalData Press Office: Email: firstname.lastname@example.org. EMEA & Americas: +44 (0)207 832 4399. Asia-Pacific: +91 40 6616 6809. To gain access to our latest press releases and expert analysis on developments in your industry, please connect with us on: GlobalData.com | LinkedIn | Twitter.
4,000 of the world’s largest companies, including over 70% of FTSE 100 and 60% of Fortune 100 companies, make more timely and better business decisions thanks to GlobalData’s unique data, expert analysis, innovative solutions, all in one platform, as well as strategy consulting services. GlobalData’s mission is to help our clients decode the future to be more successful and innovative across a range of industries, including the healthcare, consumer, retail, financial, technology, energy and professional services sectors. PR3435
In this press release references to “Deloitte” are references to one or more of Deloitte Touche Tohmatsu Limited (“DTTL”) a UK private company limited by guarantee, and its network of member firms, each of which is a legally separate and independent entity. Please see deloitte.com/about for a detailed description of the legal structure of DTTL and its member firms.Deloitte LLP is a subsidiary of Deloitte NWE LLP, which is a member firm of DTTL, and is among the UK’s leading professional services firms. The information contained in this press release is correct at the time of going to press. For more information, please visit www.deloitte.co.uk
Total Page Views: 357